SSRIs for Premenstrual Syndrome and Premenstrual Dysphoric Disorder

Donna Cohen, MD, MSc,
Deputy Director, Lancaster General Family and Community Medicine Residency Program, Lancaster, Pennsylvania

American Family Physician. 2026;114(5):467-468.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

CLINICAL QUESTION

Are selective serotonin reuptake inhibitors (SSRIs) safe and effective for the management of symptoms in patients with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)?

EVIDENCE-BASED ANSWER

SSRIs likely reduce overall symptom severity in patients with PMS or PMDD compared with placebo.1 Continuous dosing may be more effective than luteal phase dosing, although both may reduce patient rating of symptoms. Adverse effects associated with SSRI use include nausea, insomnia, decreased energy, and sexual dysfunction. (Strength of Recommendation: B, inconsistent or limited-quality patient-oriented evidence.)

PRACTICE POINTERS

Premenstrual disorders, which include PMS and PMDD, occur during the luteal phase of the menstrual cycle.1,2 PMS affects many menstruating patients and can result in marked functional impairment. Up to 6% of women meet criteria for PMDD, a more severe form of PMS that is characterized by significant mood lability, irritability, or depressed mood.2 Authors of this Cochrane review sought to evaluate the effectiveness and safety of SSRIs in the management of PMS and PMDD.

This Cochrane review included 34 randomized controlled trials with 4,563 patients ages 18 to 49 years with a diagnosis of severe PMS or PMDD (more significant psychological symptoms and longer symptom duration than PMS).1 The SSRIs fluoxetine, paroxetine, sertraline, escitalopram, and citalopram in varying doses were compared with placebo. Primary outcome was overall self-rated premenstrual symptoms (eg, depression, anxiety, irritability); secondary outcomes included response rate, adverse events, and specific symptoms of PMS or PMDD. Validated symptom scales, including daily symptom diaries and standardized premenstrual symptom scales, were used across trials. Trial duration varied but typically ranged from two to six menstrual cycles. The review evaluated the 12 most common and serious SSRI-associated adverse events (ie, nausea, insomnia, sexual dysfunction, fatigue, presyncope or vertigo, tremor, somnolence, diaphoresis, xerostomia, asthenia, diarrhea, and constipation). Most trials were conducted in high-income settings, and approximately 68% of the studies were funded by pharmaceutical companies.

SSRIs moderately improved self-rated global premenstrual symptoms compared with placebo across dosing groups (standardized mean difference [SMD] = −0.57; 95% CI, −0.72 to −0.42; 12 studies; n = 1,742; moderate-certainty evidence).1 When dosing strategy was examined, luteal phase (typically the 14 days before menses) and continuous daily regimens were more effective than placebo, but continuous dosing was associated with a larger effect size than luteal phase dosing (SMD = −0.69 vs −0.39; P = .03 for subgroup difference). The review did not include head-to-head comparisons among individual SSRIs, suggesting that the choice of SSRI may be guided by previous patient experience with and response to SSRIs, drug interactions, and patient preference.

Adverse effects were more common with SSRIs than placebo.1 Common SSRI-associated adverse events included nausea (number needed to harm [NNH] = 7); asthenia (NNH = 10); somnolence (NNH = 16); dry mouth (NNH = 16); insomnia (NNH = 20); and sexual dysfunction (NNH = 25).

The overall certainty of evidence was rated moderate because of incomplete reporting of randomization and allocation methods, suspected publication bias, and substantial pharmaceutical sponsorship.1

The American College of Obstetricians and Gynecologists practice guidelines recommend SSRIs as first-line pharmacotherapy for the management of affective premenstrual symptoms.3 The SSRIs currently approved by the US Food and Drug Administration for treatment of PMDD are fluoxetine, sertraline, and paroxetine. Before initiating pharmacotherapy, clinicians should engage in shared decision-making that incorporates patient preferences, reproductive plans, coexisting mood disorders, and adverse effects.

Author Disclosure: No relevant financial relationships.

  1. 1.Jespersen C, Lauritsen MP, Frokjaer VG, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database Syst Rev. 2024(8):CD001396.
  2. 2.Biggs WS, Romeu JM, Gaudard T. Premenstrual syndrome and premenstrual dysphoric disorder: common questions and answers. Am Fam Physician. 2025;111(4):345-350.
  3. 3.Management of premenstrual disorders: ACOG Clinical Practice Guideline No. 7. Obstet Gynecol. 2023;142(6):1516-1533.

These are summaries of reviews from the Cochrane Library.

This series is coordinated by Corey D. Fogleman, MD, assistant medical editor.

A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.